https://dermfield.com/articles/twice-daily-vdphl01-adds-43-9-hairs-cm2-at-one-year-in-male-alopecia-trial Derm Field en 2026-11-11T05:59:27.023Z Twice-Daily VDPHL01 Adds 43.9 Hairs/cm² at One Year in Male Alopecia Trial https://dermfield.com/articles/litifilimab-delivers-sustained-skin-clearance-in-cutaneous-lupus-through-52-week Derm Field en 2026-11-11T05:59:27.023Z Litifilimab Delivers Sustained Skin Clearance in Cutaneous Lupus Through 52 Weeks https://dermfield.com/articles/brepocitinib-clears-skin-in-69-with-cutaneous-sarcoidosis Derm Field en 2026-11-11T00:29:27.547Z Brepocitinib clears skin in 69% with cutaneous sarcoidosis https://dermfield.com/articles/dupilumab-and-growth-in-severe-pediatric-atopic-dermatitis Derm Field en 2026-11-11T00:19:29.357Z Dupilumab and Growth in Severe Pediatric Atopic Dermatitis https://dermfield.com/articles/high-risk-gep-results-can-trigger-slnb-and-imaging-in-early-melanoma Derm Field en 2026-11-10T16:44:26.983Z High-Risk GEP Results Can Trigger SLNB and Imaging in Early Melanoma https://dermfield.com/articles/alopecia-areata-in-practice-a-50-scalp-loss-case-dismissed-as-stress Derm Field en 2026-11-10T16:44:26.983Z Alopecia Areata in Practice: A 50% Scalp Loss Case Dismissed as Stress https://dermfield.com/articles/alopecia-areata-hair-regrowth-rebuilt-a-life-but-relapse-fear-persists Derm Field en 2026-11-10T16:44:26.983Z Alopecia Areata: Hair Regrowth Rebuilt a Life, but Relapse Fear Persists https://dermfield.com/articles/nad-backs-dove-s-24-hour-moisture-claims-after-p-g-challenge Derm Field en 2026-11-10T15:49:25.797Z NAD backs Dove's 24-hour moisture claims after P&G challenge https://dermfield.com/articles/prame-and-hla-typing-practical-guidance-for-melanoma-care Derm Field en 2026-11-10T15:39:25.617Z PRAME and HLA Typing: Practical Guidance for Melanoma Care https://dermfield.com/articles/after-frontline-immunotherapy-fails-panel-maps-next-moves-in-melanoma Derm Field en 2026-11-10T15:39:25.617Z After Frontline Immunotherapy Fails: Panel Maps Next Moves in Melanoma https://dermfield.com/articles/rogaine-sales-climb-30-as-glp-1-users-seek-hair-loss-relief Derm Field en 2026-11-10T10:19:26.351Z Rogaine Sales Climb 30% as GLP-1 Users Seek Hair Loss Relief https://dermfield.com/articles/two-dose-neoadjuvant-pembrolizumab-yields-55-6-pcr-in-resectable-cscc Derm Field en 2026-11-10T06:09:26.932Z Two-Dose Neoadjuvant Pembrolizumab Yields 55.6% pCR in Resectable cSCC https://dermfield.com/articles/bimekizumab-sustains-acr50-edge-over-risankizumab-in-psa-at-week-24 Derm Field en 2026-11-10T04:09:28.012Z Bimekizumab sustains ACR50 edge over risankizumab in PsA at week 24 https://dermfield.com/articles/thaioil-backs-viridis-2-2m-co2-surfactant-scale-up Derm Field en 2026-11-10T04:09:28.012Z Thaioil backs Viridi’s £2.2m CO2 surfactant scale-up https://dermfield.com/articles/stage-iv-melanoma-at-50-nine-months-to-live-six-years Derm Field en 2026-11-10T00:44:28.664Z Stage IV Melanoma at 50: Nine Months to Live, Six Years On https://dermfield.com/articles/radiation-dermatitis-timeline-grades-and-skin-care Derm Field en 2026-11-10T00:44:28.664Z Radiation Dermatitis: Timeline, Grades, and Skin Care https://dermfield.com/articles/oral-psoriasis-therapies-54-pasi-100-and-dosing-differences Derm Field en 2026-11-10T00:24:26.375Z Oral psoriasis therapies: 54% PASI 100 and dosing differences https://dermfield.com/articles/patient-says-he-offered-thousands-out-of-pocket-for-a-psoriasis-biologic Derm Field en 2026-11-09T15:54:24.326Z Patient Says He Offered Thousands Out of Pocket for a Psoriasis Biologic https://dermfield.com/articles/estee-lauder-companies-unveils-skin-longevity-platform Derm Field en 2026-11-09T15:29:25.064Z Estée Lauder Companies unveils skin longevity platform https://dermfield.com/articles/medicube-lands-in-1-300-shoppers-drug-mart-stores-across-canada Derm Field en 2026-11-09T11:09:26.444Z Medicube Lands in 1,300 Shoppers Drug Mart Stores Across Canada https://dermfield.com/articles/boots-launches-seven-line-k-wellness-range-in-the-uk Derm Field en 2026-11-09T11:09:26.444Z Boots launches seven-line K-Wellness range in the UK https://dermfield.com/articles/personalized-mrna-vaccine-cuts-melanoma-recurrence-risk-42-in-phase-3 Derm Field en 2026-11-09T10:34:24.157Z Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk 42% in Phase 3